Biotech

Amgen to Acquire Rodeo Therapeutics Corporation

The Conversation (0)

Portage Biotech to Present at Oppenheimer's 33rd Annual Healthcare Conference

Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company's management team will be presenting virtually at Oppenheimer's 33 rd Annual Healthcare Conference on March 13-15, 2023. Presentation details are below:

Oppenheimer 33 rd Annual Healthcare Conference

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Cardiol Therapeutics Announces Study Results from Collaborating Research Center Demonstrating Cardioprotective Effects of Cannabidiol in a Model of Heart Failure

Results Demonstrate Cannabidiol Improved Cardiac Function, Reduced its Inflammatory State, and Prevented the Development of Hypertrophy and Fibrosis in Heart Tissue

Data Presented at The American College of Cardiology's 72nd Annual Scientific Session Together with the World Congress of Cardiology

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents ($0.57) per share on the $.10 par value common stock of the company. The dividend is payable on May 1, 2023, to stockholders of record at the close of business on April 10, 2023.

In addition, the Board of Directors has declared a quarterly dividend of fifty cents ($0.50) per share on the company's $2.00 convertible preferred stock, payable on June 1, 2023, to stockholders of record at the close of business on May 2, 2023.

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

AMGEN TO PRESENT AT THE 43RD ANNUAL TD COWEN HEALTHCARE CONFERENCE

Amgen (NASDAQ:AMGN) will present at the 2023 TD Cowen Healthcare Conference at 11:10 a.m. ET on Wednesday March 8, 2023. Murdo Gordon executive vice president of Global Commercial Operations and Peter H. Griffith executive vice president and chief financial officer at Amgen will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Bristol Myers Squibb Receives European Commission Approval of Reblozyl® for Anemia in Adult Patients with Non-Transfusion-Dependent Beta Thalassemia

Third authorized indication in Europe for Reblozyl , a first-in-class treatment for patients with diseases impacted by anemia

Bristol Myers Squibb (NYSE: BMY) today announced that the European Commission (EC) has granted full Marketing Authorization for Reblozyl ® (luspatercept), a first-in-class therapeutic option, for treatment in adult patients of anemia associated with non-transfusion-dependent (NTD) beta thalassemia. Reblozyl is currently approved in the European Union (EU), United States and Canada to address anemia associated with transfusion-dependent beta thalassemia and transfusion-dependent lower-risk myelodysplastic syndromes. The centralized Marketing Authorization approves use of Reblozyl in all EU member states, as well as Norway, Iceland and Liechtenstein.*

News Provided by Business Wire via QuoteMedia

Keep reading...Show less

Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33 rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format.

Oppenheimer 33 rd Annual Healthcare Conference
Presentation Details:
Date: Monday, March 13, 2023
Time: 12:40 – 1:10 PM ET
Format : Fireside Chat - William G. Rice, PhD, Chairman, President and Chief Executive Officer, Aptose, with Matthew Biegler, Senior Analyst, Emerging Biotechnology, Oppenheimer
Webcast: LINK

The audio webcast will be archived shortly after the live event and will be available through the Aptose website, www.aptose.com .

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×